

# FAK [pY861] ABfinity™ Recombinant Rabbit Monoclonal Antibody - Purified

Catalog no. 700154

(See product label for lot information)



**Clone/PAD:** 26H16L4  
**Isotype:** IgG  
**Gene ID:** 5747  
**Protein Acc. no.:** Q05397  
**Qty:** 100 µg  
**Volume:** 200 µl  
**Concentration:** 0.5 mg/mL

## Formulation

PBS + 0.09% sodium azide

## Validation

See [www.invitrogen.com/antibodies](http://www.invitrogen.com/antibodies) for protocols

Validated for use in WB and IF

## Reactivity

This antibody is specific for FAK [pY861] and does not recognize the non-phosphorylated FAK protein.

## Immunogen

Peptide

## Immunogen sequence

LQGPIGNQHIpYQPVGKPDPA

## Sequence Identity

Human

## Sequence Homology

Dog, horse, mouse, rat and bovine

## Expected Reactivity

Based on sequence identity and similarity, reactivity to human, dog, horse, mouse, rat and bovine is expected.

## Storage

2-8°C for up to 1 month, -20°C for long term storage. Avoid repeated freezing and thawing.

## Expiration Date

Expires one year from date of receipt when stored as instructed.

## Background

FAK (Focal adhesion kinase) is a non-receptor protein-tyrosine kinase of signaling pathways and is involved in cell motility, proliferation and apoptosis (6). FAK activation leads to autophosphorylation Tyr397, which binds to the Src family kinases. Tyrosine 861 on FAK is a major Src phosphorylation site (2, 4, 7, 8). Recent evidences of FAK activity in human carcinoma cells indicate that FAK is an important target in cancer research(1, 3 - 5)

## References

1. Cai, G.Q., Zheng, A., Tang, Q., White, E.S., Chou, C.F., Gladson, C.L., Olman, M.A., and Ding, Q. Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts. *Experimental cell research* 316, 1600-1609.
2. Giannoni, E., Chiarugi, P., Cozzi, G., Magnelli, L., Taddei, M.L., Fiaschi, T., Buricchi, F., Raugei, G., and Ramponi, G. (2003). Lymphocyte function-associated antigen-1-mediated T cell adhesion is impaired by low molecular weight phosphotyrosine phosphatase-dependent inhibition of FAK activity. *The Journal of biological chemistry* 278, 36763-36776.
3. Golubovskaya, V.M., Conway-Dorsey, K., Edmiston, S.N., Tse, C.K., Lark, A.A., Livasy, C.A., Moore, D., Millikan, R.C., and Cance, W.G. (2009a). FAK overexpression and p53 mutations are highly correlated in human breast cancer. *International journal of cancer* 125, 1735-1738.
4. Golubovskaya, V.M., Zheng, M., Zhang, L., Li, J.L., and Cance, W.G. (2009b). The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. *BMC cancer* 9, 280.
5. Lane, D., Goncharenko-Khaider, N., Rancourt, C., and Piche, A. Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. *Oncogene* 29, 3519-3531.
6. Mian, M.F., Kang, C., Lee, S., Choi, J.H., Bae, S.S., Kim, S.H., Kim, Y.H., Ryu, S.H., Suh, P.G., Kim, J.S., et al. (2008). Cleavage of focal adhesion kinase is an early marker and modulator of oxidative stress-induced apoptosis. *Chemico-biological interactions* 171, 57-66.
7. Schaller, M.D., Hildebrand, J.D., Shannon, J.D., Fox, J.W., Vines, R.R., and Parsons, J.T. (1994). Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. *Molecular and cellular biology* 14, 1680-1688.
8. Thannickal, V.J., Lee, D.Y., White, E.S., Cui, Z., Larios, J.M., Chacon, R., Horowitz, J.C., Day, R.M., and Thomas, P.E. (2003). Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. *The Journal of biological chemistry* 278, 12384-12389.

For research use only. CAUTION: Not for human or animal therapeutic or diagnostic use.

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

PI700154 (Rev 08/10) DCC-10-2035

Page 1 of 2


FORM-00089 (Rev 0.0)

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, [www.invitrogen.com](http://www.invitrogen.com)). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

Following applications had been tested during development. To make sure the consistency and reliability in the future lots, each lot is tested with antigen ELISA for specificity and potency. Each lot is also tested with SDS-PAGE, to ensure high purity.



Applications:

	Species	Test Material	Concentration
Western Blotting	Human	HeLa + Pervanadate	0.5-2 µg/ml
Immunofluorescence	Human	HeLa + Pervanadate	5-10 µg/ml



Western Blot of FAK [pY861] labeled with rabbit anti-FAK [pY861] (Cat. No. 700154).

Rabbit anti-FAK [pY861] (2 µg/ml) was used to label phosphorylated FAK [pY861] in HeLa treated with pervanadate cell lysate (30 µg/lane). Lane 1 was reacted with rabbit anti FAK [pY861] without any competition, while lane 2 and 3 show competition with the specific phosphopeptide (lane 2) or non-phosphopeptide (lane 3) respectively. The western was performed using the WesternBreeze® kit with NBT/BCIP as the substrate (Cat.No.WB7105).



Immunocytochemistry of Pervanadate treated HeLa cells labeled with rabbit anti-FAK [pY861] (Cat. No. 700154).

Pervanadate treated HeLa cells were labeled with rabbit anti-FAK [pY861] (10 ug/ml). Alexa Fluor® 488 goat anti-rabbit (Cat. No. A11008) was used at 1:1000 as secondary antibody. Images shown from TOP left to right: DAPI only (blue), FAK [pY861] (AF488) signal only (green) and BOTTOM left to right:Alexa Fluor® 594 Phalloidin (red) and the composite image.

Explanation of symbols			
Symbol	Description	Symbol	Description
	Catalogue Number		Batch code
	Research Use Only		In vitro diagnostic medical device
	Use by		Temperature limitation
	Manufacturer		European Community authorised representative
	Without, does not contain		With, contains
	Protect from light		Consult accompanying documents
	Directs the user to consult instructions for use (IFU), accompanying the product.		

For research use only. CAUTION: Not for human or animal therapeutic or diagnostic use.

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.